Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02836145
Other study ID # NTU-REC-201603059RINA
Secondary ID
Status Not yet recruiting
Phase N/A
First received July 14, 2016
Last updated July 14, 2016
Start date August 2016

Study information

Verified date July 2016
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority Taiwan : Food and Drug Administration
Study type Observational

Clinical Trial Summary

Female urinary incontinence and pelvic organ prolapse are common diseases especially in aged women that frequently cause urogenital infection, voiding difficulty, urinary retention, pelvic pain, constipation, and coital difficulty, as well as impact the quality of life of women. Risk factors of the above diseases include pregnancy, vaginal delivery, and menopausal status. Despite playing a crucial role in the pathophysiology of the above diseases, the urogenital skeletal muscular dysfunction cannot be fully corrected via the current treatment modalities.

The human induced pluripotent stem cells (hiPSCs) represent a prime candidate cell type for current research and future cell therapy because of their significant self-renewal, differentiation potential and the relative lack of ethical conflict. With the advent of efficient technology of reprogramming peripheral blood mononuclear cells (PBMCs) into hiPSCs, researchers can generate personalized lines of cells from which it will be possible to obtain differentiated cells in a less invasive way, introducing opportunities in treating diseases that are now considered incurable.

Until very recently, little success has been achieved in terms of skeletal muscle differentiation from hiPSCs. The purpose of this study is to explore the applicability of the differentiation into skeletal muscle progenitor cells from hiPSC cell lines and the associated biomolecular messages. It is anticipated that the derived skeletal muscle progenitor cells can be reprogrammed from PBMCs of female patients with urinary incontinence and/or pelvic organ prolapse and used in preclinical testing for relieving female urogenital problems.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 6
Est. completion date
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- human induced pluripotent stem cells, hiPSCs

Exclusion Criteria:

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
Differentiation of hiPSCs to skeletal muscle progenitors


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Cell count Day 50 No